The use of metformin, first-line therapy for DM, is associated with a decreased incidence of HCC, whereas insulin, generally used by patients with longer duration of DM or more complications, is associated with an increased incidence of HCC. This evidence concerns the gene INS and hepatocellular carcinoma.